Complications of Treatment

• Resistance to TKIs: General mechanisms of resistance
• Resistance to TKIs: Therapeutic strategies to overcome EGFR
• Resistance to TKIs: Therapeutic strategies to overcome ALK and ROS1
• Resistance to TKIs: Focus on local treatment options
• Interactions of immunotherapy with other therapies
• Are current NTCP models useful for predicting radiation-induced toxicity?
• ESMO E-Learning: Management of Cancer Associated Thrombosis
• Symptomatic Radiation Necrosis Linked To Immunotherapy Use During Brain Metastases Radiation
• IMA950 multipeptide vaccine adjuvanted with Poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients (11PD)
• Divergent PD-1 Expression in Tissue and Circulating CD8 Lymphocytes Defines an Immune Profile Predictive of the Response to Nivolumab in Advanced N...
• Tumor-infiltrating lymphocytes, tumor-associated macrophages and HLA class 1 expression in breast cancer patients treated with neoadjuvant chemothe...
• T cell recognition of breast cancer antigens (65P)
• Overcoming resistance to anti-HER2 therapies
• Mechanisms of resistance to endocrine and biological agents
• Extensive cutaneous metastases: A separate entity?
• Management of neurotoxicity
• How can physicians help to avoid or treat side effects?
• Management of new side effects
• Patient reported outcomes during long term treatment with PD-1 inhibitors focusing on chronic toxicity and quality of life (LBA7)
• Toxicity and quality of life
• Nausea and vomiting not caused by chemotherapy: Latest studies on aetiology based treatment
• Management of immunotherapy-related toxicities
• Cardiovascular disease
• Preservation of fertility
• Second malignancy in the breast

• « Previous
• 1
• 2
• ...
• 33
• Next »